‘You Don’t Put Your Head in the Sand for 4 Years’: Colossal CEO Ben Lamm on Working With Trump

Colossal Biosciences raised $230 million in a Series C at a $10.2 billion valuation last year and is reportedly seeking a new round valuing it at $20 billion–$30 billion; no new financing was announced. CEO Ben Lamm said the company has made 130 edits to mammoth genes, but Colossal will miss its initial 2028 mammoth target. Critics say its de-extinction claims overstate scientific progress and could distract from conservation, while Lamm defended the company’s endangered-species biobanking work.

Analysis

The investable signal is less “de-extinction” than the conversion of political access into durable contracts, permissions, or public funding. Administration support for a biobank could create valuable sample infrastructure, but favorable rhetoric is not evidence of recurring revenue; verify contract value, funding source, sample-access terms, and whether agencies can sustain the program across administrations. That distinction matters to Colossal’s proposed step-up from its last reported private valuation: a conservation narrative may help fundraising, while missed milestones and criticism over species claims increase diligence and down-round risk if investors demand proof of commercial output.

The company’s strongest second-order asset may be its biological platform and sample library, not recreated animals. If those assets support independently validated applications—such as conservation monitoring or microbial plastic degradation—value could accrue through spinouts or partnerships without a mammoth milestone. Conversely, bundling conservation work with genetically enhanced working dogs creates a reputational and regulatory liability: one controversy could reduce NGO, academic, or agency participation in the broader biobank effort.

Near term, expect headline-driven private-market attention rather than a clean public-equity read-through; Colossal and Warhound are private, and any benefit to listed gene-editing or laboratory-tool companies is too diffuse to underwrite a trade. Over 1–3 months, fundraising terms and verifiable government commitments matter more than another announcement. Over 6–18 months, the thesis strengthens only if Colossal publishes independently reviewable technical results and recurring customer economics. The contrarian risk is that “conservation infrastructure” is a credible strategic pivot—but investors may be pricing that option before evidence shows it can offset the gap between ambitious claims and deliverables.

Key Decisions for Investors

• No direct public-equity trade on this article alone. Treat Colossal’s prospective financing valuation as a private-market signal, not a mark for listed gene-editing companies.
• For any private-market exposure, require the financing documents and diligence: committed versus targeted capital, dilution and preferences, milestone definitions, audited spinout economics, and revenue concentration.
• Set an alert for independently verified government awards or contracts, including amounts, duration, renewal authority, and whether funding is appropriated; a cooperation announcement without these details does not validate the revenue thesis.
• Reassess the platform thesis if the company misses further stated milestones, cannot substantiate technical claims with external review, or faces restrictions that impede sample collection or access. Evidence of repeatable customer revenue or validated conservation outcomes would be the principal upside catalyst.